PDT Partners’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

PDT Partners’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-49,159	Closed	-$850K	–	622
2015 Q4	$850K	Sell	49,159 -156,381	-76%	-$2.8M	0.12%	223
2015 Q3	$4.08M	Buy	205,540 +115,043	+127%	+$2.64M	0.09%	269
2015 Q2	$1.49M	Buy	90,497 +23,444	+35%	+$407K	0.04%	581
2015 Q1	$1.04M	Buy	+67,053	New	+$1.04M	0.03%	785
2014 Q2	–	Sell	-16,395	Closed	-$117K	–	1781
2014 Q1	$117K	Buy	+16,395	New	+$140K	﹤0.01%	1276

Other funds holding SCMP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

PDT Partners's SCMP Position: Q1 2016 in Review

PDT Partners sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2016, closing a stake of 49,159 shares — an estimated $850K sold.

PDT Partners first reported a position in SCMP in Q1 2014 and held it in 5 quarters. The position peaked at $4.08M in Q3 2015. 134 funds tracked by Wall St. Rank hold SCMP as of Q1 2016.

PDT Partners reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
PDT Partners sold 49,159 Sucampo Pharmaceuticals, Inc. shares in Q1 2016, an estimated $850K.
PDT Partners first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2014 and held it in 5 quarters.
PDT Partners's Sucampo Pharmaceuticals, Inc. position peaked at $4.08M in Q3 2015.
134 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2016.

Based on PDT Partners's 13F filing for Q1 2016, filed 16 May 2016.